Evidence map›Paper›PMID 26073293›Full record

ArticleNeurotoxicology and teratology

Selective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDD.

Kelly R Genskow, Joshua M Bradner, Muhammad M Hossain, Jason R Richardson, W Michael Caudle

Open access · greenAbstract read
In one paragraph

Article in Neurotoxicology and teratology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Update of the risk assessment of hexabromocyclododecanes (HBCDDs) in food.EFSA journal. European Food Safety Authority · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kelly R GenskowDepartment of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322-3090, USA.
Joshua M BradnerDepartment of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322-3090, USA; Center for Neurodegenerative Disease, School of Medicine, Emory University, Atlanta, GA 30322-3090, USA.
Muhammad M HossainDepartment of Environmental and Occupational Medicine, Robert Wood Johnson Medical School Piscataway, NJ 08854, USA.
Jason R RichardsonDepartment of Environmental and Occupational Medicine, Robert Wood Johnson Medical School Piscataway, NJ 08854, USA.
W Michael CaudleDepartment of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322-3090, USA; Center for Neurodegenerative Disease, School of Medicine, Emory University, Atlanta, GA 30322-3090, USA. Electronic address: william.m.caudle@emory.edu.
Emory University · USJohnson University · US

Funding

Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
Pilot Project ProgramP30ES019776 · NIEHS · EMORY UNIVERSITY · PI Carmen Joseph Marsit · 2013 to 2026
$22.6M
Graduate and Postdoctoral Training in ToxicologyT32ES012870 · NIEHS · EMORY UNIVERSITY · PI Carmen Joseph Marsit · 2004 to 2026
$9.1M
Gene-Environment Interactions in Neurodegeneration: Role of Efflux TransportersR01ES021800 · NIEHS · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI ALEKSUNES, LAUREN M, RICHARDSON, JASON R · 2014 to 2018
$1.9M
Vesicular monoamine transporter 2 as a mediator of PBDE neurotoxicityR00ES017477 · NIEHS · EMORY UNIVERSITY · PI CAUDLE, WILLIAM MICHAEL · 2010 to 2012
$737k
NIEHS NIH HHS P30 ES005022NIEHS NIH HHS P30 ES019776NIEHS NIH HHS R00 ES017477NIEHS NIH HHS R01 ES021800NIEHS NIH HHS T32 ES012870
6 · The paper itself

Abstract

Over the last several decades, the use of halogenated organic compounds has become the cause of environmental and human health concerns. Of particular notoriety has been the establishment of the neurotoxicity of polychlorinated biphenyls (PCBs) and polybrominated diphenyl ethers (PBDEs). The subsequent banning of PBDEs has led to greatly increased use of 1,2,5,6,9,10-hexabromocyclododecane (HBCDD, also known as HBCD) as a flame retardant in consumer products. The physiochemical similarities between HBCDD and PBDEs suggest that HBCDD may also be neurotoxic to the dopamine system, which is specifically damaged in Parkinson disease (PD). The purpose of this study was to assess the neurotoxicity of HBCDD on the nigrostriatal dopamine system using an in vitro and in vivo approach. We demonstrate that exposure to HBCDD (0-25 μM) for 24 h causes significant cell death in the SK-N-SH catecholaminergic cell line, as well as reductions in the growth and viability of TH+ primary cultured neurons at lower concentrations (0-10 μM) after 72 h of treatment. Assessment of the in vivo neurotoxicity of HBCDD (25 mg/kg for 30 days) resulted in significant reductions in the expression of the striatal dopamine transporter and vesicular monoamine transporter 2, both of which are integral in mediating dopamine homeostasis and neurotransmission in the dopamine circuit. However, no changes were seen in the expression of tyrosine hydroxylase in the dopamine terminal, or striatal levels of dopamine. To date, these are the first data to demonstrate that exposure to HBCDD disrupts the nigrostriatal dopamine system. Given these results and the ubiquitous nature of HBCDD in the environment, its possible role as an environmental risk factor for PD should be further investigated.

Indexed as

AnimalsCell LineCell SurvivalCorpus StriatumDopamineDopamine Plasma Membrane Transport ProteinsFlame RetardantsGABA Plasma Membrane Transport ProteinsHumansHydrocarbons, BrominatedMaleMesencephalonMiceMice, Inbred C57BLNeuritesNeuronsDopamineDopamine Plasma Membrane Transport ProteinsFlame RetardantsGABA Plasma Membrane Transport ProteinshexabromocyclododecaneHydrocarbons, BrominatedSlc18a2 protein, ratSlc32a1 protein, ratTyrosine 3-MonooxygenaseVesicular Glutamate Transport ProteinsVesicular Inhibitory Amino Acid Transport ProteinsVesicular Monoamine Transport ProteinsDopamineDopamine transporterHexabromocyclododecaneNeurotoxicityParkinson diseaseVesicular monoamine transporter 2

Identifiers

PMID26073293
PMCPMC4676947
OpenAlexW1537800061

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.